• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22857 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Satralizumab (neuromyelitis optica spectrum disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2002     Finnish Office for Health Care Technology Assessment (Finohta) [Satakunta Macropilot Project: outcomes evaluation]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Sapropterin in patients with phenylketonuria]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide (Addendum to Commission A15-18)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Safinamide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, efficacy, and economic evaluation of the implementation of an abdominal aortic aneurysm screening program]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, effectiveness and efficiency of glucometers, gasometers and coagulometers]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety of non-reabsorbable clips in living donor laparoscopic nephrectomy]
2013     Andalusian Health Technology Assessment Area (AETSA) [Safety of natural therapies with direct impact on health: Acupuncture]
2013     Andalusian Health Technology Assessment Area (AETSA) [Safety and efficacy of therapeutic hypothermia for acute ischemic stroke. Systematic review and Meta-analysis]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Safety and efficacy of the different techniques of left ventricular reconstructive surgery]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and efficacy of Thai massage as a therapeutic intervention in clinical pathologies]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new electrophysiology catheters]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2011     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and efficacy of metformin in improving clinical, hormonal and metabolic features of polycystic ovary syndrome. Systematic review and meta-analysis ]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of mechanical thrombectomy using stents retrievers in the treatment of acute isquemic stroke]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of drug eluting balloon angioplasty for coronary artery stenosis: in-stent restenosis and de novo lesions]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of antibody-coated stent for the treatment of de novo coronary artery disease]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and effectiveness of percutaneous tricuspid valve repair]
2012     Andalusian Health Technology Assessment Area (AETSA) [Safety and effectiveness of oncolytic viruses in advanced cancer. systematic review of the literature]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of LDL-aphaeresis in cerebrotendinous xanthomatosis]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Safety and cost-effectiveness of a diagnostic decision rule for suspected deep venous thrombosis in thrombosis in general practice]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan: addendum to commission A15-60]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation for the treatment of voiding dysfunction]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Sacral nerve stimulation for fecal incontinence]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Sacral nerve stimulation (SNS) for fecal incontinence]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib (Addendum to Commission A15-13)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rurioctocog alfa pegol (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [RRM1 RNA RT-PCR quantification]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Roux-en-Y gastric bypass for treating obesity]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Routine use of CYP-test in antipsychotic drug treatment - a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Routine analysis requesting profiles in primary healthcare: comparison of guidelines and cost analyses in the Basque country]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rotigotine for Parkinson’s disease]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rotavirus vaccination - a health technology assessment]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ropeginterferon alfa-2b (polycythaemia vera) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Romiplostim (Nplate) and eltrombopag (Revolade) for the treatment of immune thrombocytopenic purpura]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]
2015     Finnish Office for Health Care Technology Assessment (Finohta) [Role of fractional exhaled nitric oxide (FeNO) measurement in the management of asthma with corticosteroids]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Robotic surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery using the da Vinci robotic telemanipulation system in hysterectomy]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic surgery for benign gynecologic disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in general and digestive surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in cardiovascular surgery]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Robotic gynecological surgery]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic assisted laparoscopic surgery for cervical and endometrial cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Robot-assisted surgery: a systematic review of effectiveness and safety for elected indications and accumulating costs]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robot-assisted surgery using da Vinci robot telemanipulation in prostatectomy]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Robot-assisted rehabilitation for incomplete spinal cord injury]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Robot Assisted Radical Prostatectomy (RARP)]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Robot assisted orthopaedic surgery]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Rivastigmine for delirium in intensive care patients, a double-blind, randomised placebo-controlled add-on trial]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Rituximab in patients with rheumatoid arthritis:systematic review and economic evaluation]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of patients with chronic lymphocytic leukemia]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of chronic immune thrombocytopenic purpura]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab biosimilars]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Risk-reducing surgery in BRCA1 or 2 mutation carriers]
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2007     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Risk-adjustment in health services evaluation]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Risk factors at the regional level for suicide in the Korean elderly]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Risk factor analysis and probability of fragility fracture in a cohort of women with bone densitometry indication]